Revolutionary Approach in Treating Age-Related Macular Degeneration

In a groundbreaking development in ophthalmology, researchers from Aalto University have identified a promising method to delay or even halt the early stages of dry age-related macular degeneration (AMD). This approach focuses on enhancing the retina’s natural defense systems using targeted heat. According to Professor Ari Koskelainen, this method could revolutionize how we manage this common disease.

Understanding Dry Age-Related Macular Degeneration

Dry AMD is a condition that affects the macula, the central part of the retina responsible for sharp and detailed vision. As people age, cellular functions and protective mechanisms weaken, exposing the back of the eye to severe oxidative stress. This leads to protein damage and the accumulation of fatty protein deposits known as “drusen,” which are the primary diagnostic markers of this type of degeneration.

Oxidative stress causes the release of free radicals that damage proteins, leading to their deformation and clumping. Patients experience a gradual loss of central vision, affecting their ability to perform daily activities such as reading and driving.

Using Heat to Stimulate Therapeutic Eye Response

The new therapeutic method involves heating the affected tissues to specific temperatures, a challenging task due to the difficulty of measuring temperature behind the retina. However, the Aalto University team has developed a technique that allows real-time temperature monitoring while heating the area with near-infrared light. This enables precise and safe control of heat to stimulate the eye’s natural healing responses at the cellular level.

When proteins within the eye become deformed, cells can respond in multiple ways. One mechanism involves heat shock proteins produced in response to stress, which can help refold damaged proteins to their original structure. If this fails, the faulty proteins are targeted for breakdown into amino acids to be recycled.

Promising Results and Next Steps

The new technique has shown positive results in animal studies involving mice and pigs. Human clinical trials in Finland are expected to begin in the spring of 2026. The first phase will focus on ensuring the safety of laser treatment before moving on to determine how often it should be repeated to achieve sustainable results.

It is important for the treatment to be repeated because the response can start to diminish a few days after therapy. Researchers anticipate that the treatment will be available in eye clinics within just three years.

Conclusion

This new technique represents a significant step towards controlling age-related dry macular degeneration. By enhancing the eye’s natural defenses, patients can experience improvements in their symptoms and potentially delay disease progression. With clinical trials on the horizon, the future looks promising for patients suffering from this debilitating condition. Supported by modern technology, the treatment could soon be available in nearby clinics, providing patients with an effective and safe therapy option.